Dr. Rosenstock has long focused on exploring novel agents and therapeutic strategies for glycemic control, and particularly early combination therapies for type 2 diabetes.
Over the last 30 years, he has participated in hundreds of clinical trials and has had an active role in the development of new oral agents, incretin-related therapies, and insulin preparations, often acting as a lead clinical investigator and scientific advisor on the design and reporting of clinical trials on novel diabetes drugs. Dr. Rosenstock has been the author or co-author of 375 peer-reviewed manuscripts (h-index 123) and hundreds of scientific abstracts. He is considered a key opinion leader in type 2 diabetes.